Graham Ian M, Catapano Alberico L, Wong Nathan D
Trinity College Dublin, Dublin, Ireland.
Adelaide Health Foundation, Tallaght Hospital, Dublin, Ireland.
Cardiovasc Diagn Ther. 2017 Apr;7(Suppl 1):S4-S10. doi: 10.21037/cdt.2017.04.04.
Examination of the current the American College of Cardiology/American Heart Association (ACC/AHA) and European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) guidelines on the prevention of cardiovascular disease and the management of dyslipidemias finds much common ground. Both note that Atherosclerotic cardiovascular disease (ASCVD) is, in most people, the product of a number of risk factors, notably tobacco exposure, hyperlipidemia, hypertension, inactivity, overweight and diabetes. They stress that risk calculators can help in the assessment of risk in apparently healthy persons. Persons with established ASCVD and many with diabetes or renal impairment are at high to very high risk and warrant intensive risk factor advice and guideline-based preventive therapies. The ACC/AHA guidelines favor the universal use of statins in all high-risk subjects and in primary prevention where the global risk exceeds 7.5% in 10 years, with a percentage reduction in low-density lipoprotein cholesterol (LDL-C) based on statin intensity as the "goal". In contrast, the ESC/EAS guidelines favor a goal or percentage-based reduction in LDL-C based on total risk and baseline LDL-C level. Both guidelines consider certain imaging and other measures to stratify risk as well as the use of non-statin therapies in those not achieving recommended targets. Perhaps the most important challenges are to stress similarities rather than differences, and to simplify communications with both healthcare professionals and the public.
审视美国心脏病学会/美国心脏协会(ACC/AHA)以及欧洲心脏病学会/欧洲动脉粥样硬化协会(ESC/EAS)目前关于心血管疾病预防和血脂异常管理的指南,可以发现诸多共同点。两者均指出,在大多数人身上,动脉粥样硬化性心血管疾病(ASCVD)是多种危险因素共同作用的结果,尤其是烟草暴露、高脂血症、高血压、缺乏运动、超重和糖尿病。它们强调风险计算器有助于评估看似健康人群的风险。已确诊ASCVD的患者以及许多糖尿病或肾功能损害患者处于高风险至极高风险,需要强化风险因素建议以及基于指南的预防性治疗。ACC/AHA指南主张在所有高危人群以及10年全球风险超过7.5%的一级预防中普遍使用他汀类药物,以低密度脂蛋白胆固醇(LDL-C)降低百分比作为基于他汀强度的“目标”。相比之下,ESC/EAS指南主张基于总体风险和基线LDL-C水平,以LDL-C降低目标值或百分比为目标。两项指南均考虑采用某些影像学检查和其他措施对风险进行分层,以及在未达到推荐目标的人群中使用非他汀类疗法。或许最重要的挑战在于强调相似之处而非差异,并简化与医疗专业人员和公众的沟通。